Cart
sales@molnova.com
BMS-817378
CAS No. 1174161-69-3
BMS-817378( BMS817378 )
Catalog No. M10591 CAS No. 1174161-69-3
BMS-817378 is a prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 106 | Get Quote |
|
| 5MG | 156 | Get Quote |
|
| 10MG | 232 | Get Quote |
|
| 25MG | 422 | Get Quote |
|
| 50MG | 618 | Get Quote |
|
| 100MG | 881 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBMS-817378
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-817378 is a prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.
-
DescriptionBMS-817378 is a prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.Solid Tumors Phase 1 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsBMS817378
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
Recptorc-Met/HGFR
-
Research AreaCancer
-
IndicationSolid Tumors
Chemical Information
-
CAS Number1174161-69-3
-
Formula Weight578.85
-
Molecular FormulaC24H18ClF2N4O7P
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC1=CC(=CC=C1C2=CN(C=C(C2=O)C(=O)NC3=CC(=C(C=C3)OC4=C(C(=NC=C4)N)Cl)F)COP(=O)(O)O)F
-
Chemical Name(Z)-N-(4-((3-chloro-2-imino-1,2-dihydropyridin-4-yl)oxy)-3-fluorophenyl)-5-(4-fluorophenyl)-4-oxo-1-((phosphonooxy)methyl)-1,4-dihydropyridine-3-carbimidic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Cabozantinib hydroch...
Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2 c-Met Kit Axl and Flt4 (IC50s: 0.035 1.3 4.6 7 and 6 nM).
-
AMG-337
AMG-337 is a potent and selective inhibitor of MET with biochemical IC50 of 1 nM; inhibits of HGF-mediated MET phosphorylation in PC3 cells.
-
Capmatinib hydrochlo...
Capmatinib hydrochloride is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Capmatinib was found to be highly selective for MET over other kinases.?It was active against cancer models that are characterized by MET amplification, marked MET overexpression, MET exon 14 skipping mutations, or MET activation via expression of the ligand hepatocyte growth factor (HGF).
